ACIU Historical Balance Sheet
ACIU Stock | USD 3.38 0.09 2.74% |
Trend analysis of AC Immune balance sheet accounts such as Other Current Liab of 9.5 M, Total Current Liabilities of 12.8 M or Total Stockholder Equity of 158.5 M provides information on AC Immune's total assets, liabilities, and equity, which is the actual value of AC Immune to its prevalent stockholders. By breaking down trends over time using AC Immune balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining AC Immune latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AC Immune is a good buy for the upcoming year.
AC Immune Inventory |
|
ACIU |
About ACIU Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of AC Immune at a specified time, usually calculated after every quarter, six months, or one year. AC Immune Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AC Immune and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ACIU currently owns. An asset can also be divided into two categories, current and non-current.
AC Immune Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of AC Immune assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in AC Immune books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on AC Immune balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of AC Immune are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Accumulated Amortization
The cumulative amount of amortization expense charged against intangible assets, like patents and copyrights, over time.Most accounts from AC Immune's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into AC Immune current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.At this time, AC Immune's Cash And Short Term Investments are comparatively stable compared to the past year. Short Term Investments is likely to gain to about 46.4 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 12.8 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 16.7M | 9.4M | 11.1M | 9.5M | Total Assets | 261.4M | 185.9M | 182.8M | 177.6M |
AC Immune balance sheet Correlations
Click cells to compare fundamentals
AC Immune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AC Immune balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 299.3M | 238.7M | 261.4M | 185.9M | 182.8M | 177.6M | |
Other Current Liab | 11.8M | 11.1M | 16.7M | 9.4M | 11.1M | 9.5M | |
Total Current Liabilities | 17.5M | 14.0M | 20.0M | 11.5M | 13.6M | 12.8M | |
Total Stockholder Equity | 272.4M | 215.5M | 232.0M | 169.0M | 160.6M | 158.5M | |
Other Liab | 7.5M | 7.5M | 7.1M | 3.2M | 3.7M | 5.0M | |
Net Tangible Assets | 272.4M | 215.5M | 181.6M | 118.6M | 136.4M | 145.5M | |
Retained Earnings | (75.5M) | (132.9M) | (200.9M) | (264.0M) | (316.2M) | (300.4M) | |
Accounts Payable | 142K | 2.2M | 2.0M | 929K | 1.7M | 1.4M | |
Cash | 193.6M | 160.9M | 82.2M | 31.6M | 78.5M | 107.1M | |
Net Receivables | 1.4M | 1.6M | 975K | 800K | 15.0M | 15.8M | |
Other Current Assets | 4.2M | 4.0M | 3.0M | 4.7M | 6.4M | 6.8M | |
Total Liab | 26.8M | 23.3M | 29.5M | 16.9M | 22.2M | 19.1M | |
Total Current Assets | 292.8M | 231.8M | 202.6M | 128.1M | 125.2M | 157.9M | |
Common Stock | 1.4M | 1.5M | 1.8M | 1.8M | 2.1M | 1.5M | |
Property Plant Equipment | 6.2M | 6.6M | 8.0M | 7.1M | 8.1M | 8.5M | |
Property Plant And Equipment Net | 6.2M | 6.6M | 8.0M | 7.1M | 6.9M | 4.7M | |
Current Deferred Revenue | 4.5M | 306K | 717K | 587K | 138K | 131.1K | |
Net Debt | (190.7M) | (158.7M) | (79.3M) | (28.8M) | (75.0M) | (78.7M) | |
Non Current Assets Total | 6.5M | 7.0M | 58.8M | 57.8M | 57.7M | 60.5M | |
Non Currrent Assets Other | 6.5M | 334K | 363K | 361K | 415.2K | 394.4K | |
Cash And Short Term Investments | 288.6M | 225.9M | 198.2M | 122.6M | 103.0M | 162.9M | |
Common Stock Total Equity | 1.1M | 1.4M | 1.4M | 1.5M | 1.8M | 1.3M | |
Common Stock Shares Outstanding | 71.1M | 71.9M | 75.0M | 83.6M | 84.7M | 73.3M | |
Short Term Investments | 95M | 65M | 116M | 91M | 24.6M | 46.4M | |
Liabilities And Stockholders Equity | 299.3M | 238.7M | 261.4M | 185.9M | 182.8M | 193.9M | |
Non Current Liabilities Total | 9.3M | 9.2M | 9.4M | 5.5M | 8.6M | 6.9M | |
Capital Lease Obligations | 2.3M | 2.2M | 2.9M | 2.8M | 3.5M | 3.7M | |
Inventory | (1.4M) | (1.9M) | (1.4M) | 1.0 | (622K) | (590.9K) | |
Other Stockholder Equity | 346.5M | 346.8M | 431.1M | 431.2M | 474.8M | 300.1M | |
Property Plant And Equipment Gross | 6.2M | 6.6M | 15.6M | 7.1M | 17.9M | 18.8M | |
Accumulated Other Comprehensive Income | 179.4M | (3.5M) | 0.0 | 10K | (51K) | (48.5K) | |
Short Term Debt | 1.1M | 443K | 570K | 548K | 672K | 402.5K | |
Short Long Term Debt Total | 2.9M | 2.2M | 2.9M | 2.8M | 3.5M | 2.1M | |
Net Invested Capital | 273.1M | 215.5M | 232.0M | 169.0M | 160.6M | 211.4M | |
Net Working Capital | 275.3M | 217.7M | 182.6M | 116.6M | 111.6M | 137.5M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.